{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T06:00:10Z","timestamp":1771740010101,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejso.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.ejso.2015.08.159","type":"journal-article","created":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T07:44:21Z","timestamp":1442043861000},"page":"140-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study"],"prefix":"10.1016","volume":"42","author":[{"given":"V.","family":"Nagaraja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Morey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.R.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.D.","family":"Eslick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejso.2015.08.159_bib1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/bjs.1800761227","article-title":"Time-related changes in characteristics of prognostic significance in carcinomas of the oesophagus and cardia","volume":"76","author":"Lund","year":"1989","journal-title":"Br J Surg"},{"issue":"12","key":"10.1016\/j.ejso.2015.08.159_bib2","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1245\/s10434-008-0155-0","article-title":"Improving the\u00a0accuracy of TNM staging in esophageal cancer: a pathological review of resected specimens","volume":"15","author":"Thompson","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"9742","key":"10.1016\/j.ejso.2015.08.159_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejso.2015.08.159_bib4","first-page":"67","article-title":"Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis","volume":"5","author":"Nagaraja","year":"2014","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2015.08.159_bib5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/jcp.2007.054866","article-title":"HER2 testing in the UK: further update to recommendations","volume":"61","author":"Walker","year":"2008","journal-title":"J\u00a0Clin Pathol"},{"issue":"4","key":"10.1016\/j.ejso.2015.08.159_bib6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1309\/AJCPV2I0HGPMGBSQ","article-title":"Emerging technologies for assessing HER2 amplification","volume":"132","author":"Penault-Llorca","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"34","key":"10.1016\/j.ejso.2015.08.159_bib7","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1200\/JCO.2009.22.1507","article-title":"Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer","volume":"27","author":"Spector","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejso.2015.08.159_bib8","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.ejso.2015.08.159_bib9","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2015.08.159_bib10","doi-asserted-by":"crossref","unstructured":"Smith I, Procter M, Gelber RD, et\u00a0al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet; 369(9555): 29\u201336.","DOI":"10.1016\/S0140-6736(07)60028-2"},{"issue":"6","key":"10.1016\/j.ejso.2015.08.159_bib11","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1007\/s13277-014-1693-7","article-title":"Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis","volume":"35","author":"Gu","year":"2014","journal-title":"Tumour Biol"},{"issue":"11","key":"10.1016\/j.ejso.2015.08.159_bib12","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1158\/1535-7163.MCT-09-0820","article-title":"A\u00a0phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2\/neu-expressing malignancies","volume":"8","author":"Bekaii-Saab","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.ejso.2015.08.159_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1600-0463.2009.02531.x","article-title":"HER2\/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens","volume":"117","author":"Lesnikova","year":"2009","journal-title":"APMIS Acta Pathol Microbiol Immunol Scand"},{"issue":"1","key":"10.1016\/j.ejso.2015.08.159_bib14","first-page":"25","article-title":"HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis","volume":"5","author":"Gowryshankar","year":"2014","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2015.08.159_bib15","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/JTO.0b013e3181f26266","article-title":"The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data","volume":"5","author":"Liu","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2015.08.159_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/gm482","article-title":"Clinical and molecular characterization of HER2 amplified-pancreatic cancer","volume":"5","author":"Chou","year":"2013","journal-title":"Genome Med"},{"issue":"2","key":"10.1016\/j.ejso.2015.08.159_bib17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejso.2015.08.159_bib18","article-title":"HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis","author":"Gowryshankar","year":"2013","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2015.08.159_bib19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.athoracsur.2013.02.069","article-title":"The Society of thoracic surgeons guidelines on the diagnosis and staging of patients with esophageal cancer","volume":"96","author":"Varghese","year":"2013","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"10.1016\/j.ejso.2015.08.159_bib20","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"issue":"10","key":"10.1016\/j.ejso.2015.08.159_bib21","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s11605-012-1979-2","article-title":"Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer","volume":"16","author":"Chan","year":"2012","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.ejso.2015.08.159_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14728222.2014.956086","article-title":"The potential for targeting HER2 therapeutically in esophageal cancer \u2013 a grasp at straws?","author":"Uzunoglu","year":"2014","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"10.1016\/j.ejso.2015.08.159_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0046-8177(00)80195-1","article-title":"HER-2\/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma","volume":"31","author":"Brien","year":"2000","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.ejso.2015.08.159_bib24","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/1078-0432.CCR-11-2272","article-title":"Association of HER2\/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas","volume":"18","author":"Yoon","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejso.2015.08.159_bib25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/modpathol.3800712","article-title":"Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus","volume":"20","author":"Reichelt","year":"2007","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.ejso.2015.08.159_bib26","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/modpathol.2011.52","article-title":"Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation","volume":"24","author":"Langer","year":"2011","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.ejso.2015.08.159_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/jcp.47.1.23","article-title":"Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations","volume":"47","author":"Flejou","year":"1994","journal-title":"J\u00a0Clin Pathol"},{"issue":"1","key":"10.1016\/j.ejso.2015.08.159_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0748-7983(97)80139-4","article-title":"Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis","volume":"23","author":"Hardwick","year":"1997","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2015.08.159_bib29","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/modpathol.2011.47","article-title":"HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma","volume":"24","author":"Hu","year":"2011","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.ejso.2015.08.159_bib30","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1245\/s10434-011-1554-1","article-title":"Her-2\/neu gene amplification in esophageal adenocarcinoma and its influence on survival","volume":"18","author":"Thompson","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2015.08.159_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/00000658-199506000-00007","article-title":"The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus","volume":"221","author":"Duhaylongsod","year":"1995","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.ejso.2015.08.159_bib32","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s002689900616","article-title":"Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3","volume":"23","author":"Friess","year":"1999","journal-title":"World J Surg"},{"issue":"5","key":"10.1016\/j.ejso.2015.08.159_bib33","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1365-2559.2011.04012.x","article-title":"Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma","volume":"59","author":"Kim","year":"2011","journal-title":"Histopathology"},{"issue":"32","key":"10.1016\/j.ejso.2015.08.159_bib34","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1200\/JCO.2012.43.1890","article-title":"Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma","volume":"30","author":"Yoon","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2015.08.159_bib35","first-page":"938","article-title":"Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance","volume":"25","author":"Seol","year":"2012","journal-title":"Mod Pathology \u2013 Off J U. S Can Acad Pathol Inc"},{"issue":"12","key":"10.1016\/j.ejso.2015.08.159_bib36","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1245\/s10434-011-1730-3","article-title":"Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression","volume":"18","author":"Birner","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2015.08.159_bib37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ccr.2008.04.005","article-title":"Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer","volume":"13","author":"Stoecklein","year":"2008","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ejso.2015.08.159_bib38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cgh.2009.10.010","article-title":"Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis","volume":"8","author":"Sikkema","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"125","key":"10.1016\/j.ejso.2015.08.159_bib39","first-page":"1063","article-title":"Amplification of Her-2\/neu oncogene in GERD \u2013 Barrett's metaplasia \u2013 dysplasia \u2013 adenocarcinoma sequence","volume":"60","author":"Mokrowiecka","year":"2013","journal-title":"Hepatogastroenterology"},{"issue":"9b","key":"10.1016\/j.ejso.2015.08.159_bib40","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1111\/j.1582-4934.2008.00517.x","article-title":"HER-2 overexpression\/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study","volume":"13","author":"Rossi","year":"2009","journal-title":"J\u00a0Cell Mol Med"},{"issue":"2","key":"10.1016\/j.ejso.2015.08.159_bib41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ijrobp.2006.08.076","article-title":"Phase I\/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma","volume":"67","author":"Safran","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"10.1016\/j.ejso.2015.08.159_bib42","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.7314\/APJCP.2014.15.13.5343","article-title":"Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer","volume":"15","author":"Luo","year":"2014","journal-title":"Asian Pac J Cancer Prev APJCP"},{"issue":"4","key":"10.1016\/j.ejso.2015.08.159_bib43","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jamcollsurg.2005.12.022","article-title":"Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients","volume":"202","author":"Portale","year":"2006","journal-title":"J\u00a0Am Coll Surg"},{"issue":"6","key":"10.1016\/j.ejso.2015.08.159_bib44","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0003-4975(01)02601-7","article-title":"Ivor Lewis esophagogastrectomy for esophageal cancer","volume":"71","author":"Visbal","year":"2001","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.ejso.2015.08.159_bib45","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0003-4975(02)04368-0","article-title":"Outcomes after esophagectomy: a ten-year prospective cohort","volume":"75","author":"Bailey","year":"2003","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"10.1016\/j.ejso.2015.08.159_bib46","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1442-2050.2011.01304.x","article-title":"Patterns of operative mortality following esophagectomy","volume":"25","author":"Schieman","year":"2012","journal-title":"Dis Esophagus"},{"issue":"4","key":"10.1016\/j.ejso.2015.08.159_bib47","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.athoracsur.2004.02.034","article-title":"Reducing hospital morbidity and mortality following esophagectomy","volume":"78","author":"Atkins","year":"2004","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"10.1016\/j.ejso.2015.08.159_bib48","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s002689900279","article-title":"Mortality after esophagectomy: risk factor analysis","volume":"21","author":"Ferguson","year":"1997","journal-title":"World J Surg"},{"issue":"1","key":"10.1016\/j.ejso.2015.08.159_bib49","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0003-4975(00)02570-4","article-title":"Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis","volume":"72","author":"Hulscher","year":"2001","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"10.1016\/j.ejso.2015.08.159_bib50","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ejcts.2009.09.034","article-title":"An alternative postoperative pathway reduces length of hospitalisation following oesophagectomy","volume":"37","author":"Tomaszek","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"issue":"21","key":"10.1016\/j.ejso.2015.08.159_bib51","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJMoa022343","article-title":"Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus","volume":"347","author":"Hulscher","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ejso.2015.08.159_bib52","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/SLA.0b013e31815c4037","article-title":"Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid\/distal esophagus: five-year survival of a randomized clinical trial","volume":"246","author":"Omloo","year":"2007","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.ejso.2015.08.159_bib53","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/SLA.0b013e31814697f2","article-title":"Two thousand transhiatal esophagectomies: changing trends, lessons learned","volume":"246","author":"Orringer","year":"2007","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.ejso.2015.08.159_bib54","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/bjs.1800770804","article-title":"Surgical therapy of oesophageal carcinoma","volume":"77","author":"M\u00fcller","year":"1990","journal-title":"Br J Surg"}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798315007313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798315007313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T09:24:03Z","timestamp":1537349043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798315007313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0748798315007313"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2015.08.159","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology (EJSO)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2015.08.159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2015 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}